Dr. Christopher Batich Appointed to Evren’s Scientific Advisory Board
- gdirks3
- 3 days ago
- 3 min read
Gainesville, FL – December 3, 2025 – Evren Technologies, Inc., a leader in neuromodulation medical devices dedicated to transforming the treatment of PTSD, acute stress reactions, and related conditions, proudly announces the appointment of Dr. Christopher Batich as a Scientific Advisor. Dr. Batich’s extensive expertise in biomedical engineering, materials science, and translational research will support Evren in advancing its pioneering technologies, including the Phoenix® 100 device, which delivers transcutaneous auricular vagus nerve stimulation (taVNS).
Dr. Batich brings over four decades of experience as a researcher, innovator, and academic leader. A professor emeritus in the Department of Materials Science and Engineering at the University of Florida (UF), he has published 160 peer-reviewed papers and holds 70 issued patents. Among his most notable contributions is Bioguard®, an advanced antibacterial wound dressing that has been used for care in burn units and nursing homes across the United States.
Dr. Batich’s career is marked by leadership in biomedical innovation. As the founding director of UF’s Graduate Biomedical Engineering Program and the founding associate director and chief operating officer of the Clinical and Translational Science Institute (CTSI), he spearheaded efforts to bridge science, engineering, and clinical care, resulting in groundbreaking advancements in patient outcomes. His work spans surface modification of polymeric materials, neurodegenerative disease drug delivery, and collaborative development of medical devices to address critical healthcare challenges.
In recognition of his impact, Dr. Batich was inducted into the Florida Inventors Hall of Fame in 2020. His guidance will be instrumental as Evren Technologies continues its mission to deliver noninvasive solutions for conditions such as PTSD and acute stress disorder, supported by the FDA's Breakthrough Device Designation for the Phoenix.
“We are thrilled to welcome Dr. Batich to our advisory team,” said Weaver Gaines, Chairman of the Board of Evren Technologies. “His deep understanding of materials science and medical device innovation aligns perfectly with our vision to revolutionize neuromodulation therapy. His leadership and insight will significantly enhance our research and development efforts as we work to bring the Phoenix® 100 to market.”
Dr. Batich joins a distinguished team of experts at Evren, including its world-class Board of Directors and Scientific Advisors, to advance the company’s pivotal clinical trials and regulatory efforts.
About Evren Technologies
Evren is a bioelectronic medical device company in the field of neuromodulation devices and is transforming the treatment of PTSD, Acute Stress Reactions, Acute Stress Disorder, and Adjustment Disorders by delivering noninvasive, breakthrough, Vagal Nerve Stimulation (VNS) to the auricular branch of the vagus nerve. Our initial product -- the Phoenix® CR – administers transcutaneous auricular VNS (taVNS) safely and effectively in laboratory, clinical, and unsupervised home settings for VNS research use and was launched in late 2023. The Phoenix CR will also be the clinical trial device in Evren’s pivotal trial seeking De Novo classification from the FDA. It will deliver safe and effective taVNS therapy, with no known adverse side effects. Bioelectronic medicine uses sophisticated technology to modulate the electrical activity of the body’s nervous system and has the potential to supplement or even replace drugs or other interventions. Evren’s technology is based on stimulating the vagus nerve, the main nerve of the parasympathetic (“calming or safety”) branch of the autonomic nervous system. For further information about the Phoenix CR or Evren Technologies, please visit evrenvns.com.
CONTACT:
Josh Kelly, Director of Operations
Evren Technologies, Inc.
904.517.2432
Comments